China to probe drug, device pricing among domestic, foreign firms

China flag

China's National Development and Reform Commission (NDRC) will launch an investigation into all aspects of drug and medical device sales and prices among domestic and foreign firms in a step that could lead to enforcement action.

In an online notice, the NDRC, which monitors prices and competition and regularly takes steps to curb monopoly practices, said the initial aim is to gather information from companies, hospitals and related industry players to assess price fluctuations amid regulatory efforts to reform the way drugs are bought and sold in China.

The probe will last through October with the impact of drug price reform over the past year to be looked at amid concern about "frequent price changes," according to the NDRC statement.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Earlier in May, China Daily tipped that a fresh look at pricing for drug and device companies was in the works and mentioned that some firms, including Pfizer ($PFE) had already been contacted for information on pricing.

China's policymakers have taken several steps to curb drug prices, including eliminating a 15% markup at 200 public hospitals nationwide on drugs prescribed and bough onsite and in a pilot program to negotiate lower patented drug prices.

Companies in China are aware that financial and other penalties for breaches of competition law can be assessed from remedial actions to a scale that saw GlaxoSmithKline ($GSK) famously pay a $489 million fine in 2014 for bribery and other charges in the sale of drugs to hospitals and doctors.

- here's the story from China Daily
- and the announcement from NDRC (Chinese language)

Suggested Articles

Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.

Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Fosun Pharma. 

GlaxoSmithKline has opened continuous manufacturing operations in Singapore that will make products faster, with less cost and less waste.